Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Ochre Bio","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Ochre Bio"},{"company":"University of Oxford","sponsor":"180 Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Peptide","graph2":"University of Oxford"}]

University of Oxford

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

Details:

Together with the University of Oxford, the Company plans to proceed with scaling up and Good Manufacturing Practice (GMP) production of HMGB1, as well as safety and toxicity testing in preparation for a planned Investigational New Drug (IND) application filing.

Lead Product(s): HMGB1

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HMGB1

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: 180 Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement December 15, 2021

ASK
US

Upload
your Pipeline Activity

Ochre Bio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures

Details:

Funding will be used to develop RNA therapies for transplant and chronic liver diseases. Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines.

Lead Product(s): RNA Therapies

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Khosla Ventures

Deal Size: $9.6 million Upfront Cash: Undisclosed

Deal Type: Financing June 16, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY